Mouse models of estrogen receptor-positive breast cancer

Journal of Carcinogenesis

Volumn 10, Issue , 2011, Pages

  Mohibi, Shakur ^a   Mirza, Sameer ^a   Band, Hamid ^a   Band, Vimla ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; estrogen receptor; mouse models

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PROGESTERONE; PROLACTIN; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CANCER RECURRENCE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; UPREGULATION;

EID: 84872732736     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.91116     Document Type: Article

References (102)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global Cancer statistics. CA Cancer J Clin 2011, 61: 69-90.
2. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: Approaches to estimating and reducing risk. J Natl Cancer Inst 2009;101:384-98.
3. McTiernan A, Porter P, Potter JD. Breast cancer prevention in countries with diverse resources. Cancer 2008;113(8 Suppl):2325-30.
4. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35. (Pubitemid 23269068)
5. Boyd J. Estrogen as a carcinogen: The genetics and molecular biology of human endometrial carcinoma. Prog Clin Biol Res 1996;394:151-73.
6. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86. (Pubitemid 24218640)
7. Mosselman S, Polman J, Dijkema R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53. (Pubitemid 26268330)
8. Masood S. Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol 1992;8:475-91.
9. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
11. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 2010;10:955-60.
12. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004;6:240-5. (Pubitemid 39440252)
13. Wagner KU. Models of breast cancer: Quo vadis, animal modeling? Breast Cancer Res 2004;6:31-8.
14. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004;15:193-7. (Pubitemid 38833988)
15. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia 2000;5:187-200. (Pubitemid 32045695)
16. Russo J, Balogh GA, Heulings R, Mailo DA, Moral R, Russo PA, et al. Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev 2006;15:306-42. (Pubitemid 44060488)
17. Russo J, Balogh G, Mailo D, Russo PA, Heulings R, Russo IH. The genomic signature of breast cancer prevention. Recent Results Cancer Res 2007;174:131-50.
18. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, et al. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res 2006;66:6421-31.
19. Medina D, Butel JS, Socher SH, Miller FL. Mammary tumorigenesis in 7,12-dimethybenzanthracene-treated C57BL x DBA/2f F1 mice. Cancer Res 1980;40:368-73. (Pubitemid 10140165)
20. Rudland PS, Fernig DG, Smith JA. Growth factors and their receptors in neoplastic mammary glands. Biomed Pharmacother 1995;49:389-99.
21. Roepstorff K, Grovdal L, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: Mechanisms and relevance in cancer. Histochem Cell Biol 2008;129:563-78.
22. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110. (Pubitemid 36331969)
23. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005;12 Suppl 1:S99-111.
24. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990;61:1137-46.
25. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 1990;61:1147-55.
26. Otten AD, Sanders MM, McKnight GS. The MMTV LTR promoter is induced by progesterone and dihydrotestosterone but not by estrogen. Mol Endocrinol 1988;2:143-7. (Pubitemid 18080063)
27. Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 1995;55:3915-27.
28. Rose-Hellekant TA, Schroeder MD, Brockman JL, Zhdankin O, Bolstad R, Chen KS, et al. Estrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss. Oncogene 2007;26:5238-46. (Pubitemid 47237633)
29. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-76. (Pubitemid 33741882)
30. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003;10:431-42. (Pubitemid 36626355)
31. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 1999;431:199-209. (Pubitemid 30017791)
32. Harvey M, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 1993;5:225-9. (Pubitemid 23330383)
33. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
34. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
35. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 2000;19:1052-8. (Pubitemid 30153789)
36. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J 2002;16:881-3.
37. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res 2003;63:1067-72. (Pubitemid 36278440)
38. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. Breast Cancer Special Feature: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA 2011.
39. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, et al. Somatic mutation of p53 leads to estrogen receptor alpha-positive and-negative mouse mammary tumors with high frequency of metastasis. Cancer Res 2004;64:3525-32. (Pubitemid 38657927)
40. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, et al. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 2005;65:8166-73. (Pubitemid 41330580)
41. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982;31:99-109.
42. Alonso L, Fuchs E. Stem cells in the skin: Waste not, Wnt not. Genes Dev 2003;17:1189-200. (Pubitemid 36583161)
43. Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, et al. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 2004;131:4819-29. (Pubitemid 39433468)
44. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988;55:619-25.
45. Kwan H, Pecenka V, Tsukamoto A, Parslow TG, Guzman R, Lin TP, et al. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 1992;12:147-54.
46. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 1995;9:882-95.
47. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 1999;59:1869-76. (Pubitemid 29186159)
48. Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, et al. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 2005;24:4220-31. (Pubitemid 40961776)
49. Fuchs-Young R, Shirley SH, Lambertz I, Colby JK, Tian J, Johnston D, et al. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat 2011;130:399-408.
50. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8. (Pubitemid 27366683)
51. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 2009;116:225-37.
52. Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T, et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003;98:18-23. (Pubitemid 36741120)
53. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61. (Pubitemid 36395255)
54. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-74. (Pubitemid 39222039)
55. Avivar A, Garcia-Macias MC, Ascaso E, Herrera G, O'Connor JE, de Mora JF. Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium. FEBS Lett 2006;580:5222-6. (Pubitemid 44415794)
56. Tilli MT, Reiter R, Oh AS, Henke RT, McDonnell K, Gallicano GI, et al. Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. Mol Endocrinol 2005;19:644-56. (Pubitemid 40349437)
57. Davis VL, Couse JF, Goulding EH, Power SG, Eddy EM, Korach KS. Aberrant reproductive phenotypes evident in transgenic mice expressing the wild-type mouse estrogen receptor. Endocrinology 1994;135:379-86. (Pubitemid 24203841)
58. Couse JF, Davis VL, Hanson RB, Jefferson WN, McLachlan JA, Bullock BC, et al. Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Mol Carcinog 1997;19:236-42. (Pubitemid 27392002)
59. Hruska KS, Tilli MT, Ren S, Cotarla I, Kwong T, Li M, et al. Conditional over-expression of estrogen receptor alpha in a transgenic mouse model. Transgenic Res 2002;11:361-72. (Pubitemid 35301747)
60. Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, et al. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol 2003;163:1713-19. (Pubitemid 37310001)
61. Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, et al. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene 2008;27:794-802. (Pubitemid 351186312)
62. Miermont AM, Parrish AR, Furth PA. Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis 2010;31:1124-31.
63. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27. (Pubitemid 36223277)
64. Binart N, Ormandy CJ, Kelly PA. Mammary gland development and the prolactin receptor. Adv Exp Med Biol 2000;480:85-92. (Pubitemid 32176097)
65. Goffin V, Kelly PA. The prolactin/growth hormone receptor family: Structure/function relationships. J Mammary Gland Biol Neoplasia 1997;2:7-17. (Pubitemid 127717408)
66. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997;138:5555-60. (Pubitemid 27509722)
67. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 1997;82:3692-9. (Pubitemid 27509357)
68. Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998;79:202-11. (Pubitemid 28201694)
69. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998;83:667-74. (Pubitemid 28496555)
70. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 2003;22:4664-74. (Pubitemid 36976441)
71. Arendt LM, Rose-Hellekant TA, Sandgren EP, Schuler LA. Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. Am J Pathol 2006;168:1365-74.
72. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 2011;13:R11.
73. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
74. Hatakeyama M, Brill JA, Fink GR, Weinberg RA. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 1994;8:1759-71.
75. Calbo J, Parreno M, Sotillo E, Yong T, Mazo A, Garriga J, et al. G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J Biol Chem 2002;277:50263-74. (Pubitemid 36042174)
76. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
77. Musgrove EA. Cyclins: Roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006;24:13-9. (Pubitemid 43108773)
78. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1:1257-60.
79. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: New insights from transgenic mouse models. Breast Cancer Res 2002;4:14-7. (Pubitemid 34097551)
80. Kim JK, Diehl JA. Nuclear cyclin D1: An oncogenic driver in human cancer. J Cell Physiol 2009;220:292-6.
81. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002;62:6916-23. (Pubitemid 35424081)
82. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999;5:2069-76. (Pubitemid 29399260)
83. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21. (Pubitemid 32612319)
84. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71. (Pubitemid 24199473)
85. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006;25:998-1007. (Pubitemid 43277008)
86. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008;27:1231-42. (Pubitemid 351294688)
87. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-7. (Pubitemid 17095859)
88. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003;546:108-12. (Pubitemid 36782290)
89. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-42. (Pubitemid 38591317)
90. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
91. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000;141:4503-11. (Pubitemid 32055127)
92. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
93. Blanco-Aparicio C, Perez-Gallego L, Pequeno B, Leal JF, Renner O, Carnero A. Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 2007;28:584-94. (Pubitemid 46523354)
94. Kumar MJ, Ponvijay KS, Nandhini R, Nagarajan RS, Jose J, Srinivas G, et al. A mouse model for luminal epithelial like ER positive subtype of human breast cancer. BMC Cancer 2007;7:180.
95. Song RX, Santen RJ. Membrane initiated estrogen signaling in breast cancer. Biol Reprod 2006;75:9-16. (Pubitemid 43946335)
96. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005;26:898-915. (Pubitemid 41770157)
97. Bachelot A, Binart N. Reproductive role of prolactin. Reproduction 2007;133:361-9. (Pubitemid 46359524)
98. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88:405-15. (Pubitemid 27131382)
99. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997;17:5338-47. (Pubitemid 27357632)
100. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-41. (Pubitemid 30070977)
101. Liu W, Ip MM, Podgorsak MB, Das GM. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: A novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Res Treat 2009;115:43-50.
102. Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, et al. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA 2010;107:15081-6.